Skip to main content
. 2020 Apr 29;10:7290. doi: 10.1038/s41598-020-64354-0

Table 4.

Comparison of clinical and pathological characteristics between patients with ALBI grade I and II/III after 1 year of curative resection.

ALBI grade I (n = 171) ALBI grade II/III (n = 66) P value
Age (years; mean ± SD) 52.4 ± 10.4 56.2 ± 12.3 0.019
Age (>60 years), n (%) 48 (28.1%) 35 (53.0%) <0.001
Male, n (%) 150 (87.7%) 56 (84.8%) 0.557
Bilirubin (g/dL; mean ± SD) 0.8 ± 0.3 0.8 ± 0.3 0.755
Albumin (g/dL; mean ± SD) 3.9 ± 0.6 3.7 ± 0.5 0.038
AFP (>15 ng/mL), n (%) 94 (55.6%) 30 (46.9%) 0.232
Liver cirrhosis, n (%) 48 (49.1%) 37 (56.1%) 0.338
NAs treatment, n (%) 63 (37.3%) 21 (32.3%) 0.635
   LAM, n (%) 8 (12.7%) 5 (23.8%)
   LdT, n (%) 2 (3.2%) 1 (4.8%)
   ETV, n (%) 45 (71.4%) 13 (61.9%)
   TDF, n (%) 8 (12.7%) 2 (9.5%)
Tumor number (single: multiple) 9: 162 2: 64 0.464
Types of surgery 0.818
   Right lobectomy, n (%) 24 (14.2%) 10 (15.4%)
   Left lobectomy, n (%) 19 (11.2%) 9 (13.8%)
   Segmentectomy, n (%) 126 (74.6%) 46 (70.8%)
Child-Pugh grade (A: B) 163: 8 60: 6 0.197
MELD score (mean ± SD) 8.0 ± 2.6 7.7 ± 3.2 0.496
ALBI grade (I: II) 80: 89 25: 40 0.221
Diabetes Mellitus 27 (15.8%) 18 (27.3%) 0.043
Micro/Macrovascular invasion, n (%) 75 (43.9%) 32 (48.5%) 0.521
pTNM stage (I: II: III) 88: 78: 5 31: 27: 8 0.021
Histological grade (well: moderate: poor) 23: 141: 7 10: 53: 3 0.928

AFP = α-fetoprotein, NAs, = nucleot(s)ide analogues, LAM = lamivudine, LdT = telbivudine, ETV = entecavir, TDF = tenofovir, MELD = model for end-stage liver disease, FIB-4 = fibrosis-4, ALBI = albumin-bilirubin.